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ABSTRACT Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-
resistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20–
24 months), toxicity, costs and sub-optimal outcomes. After over 40 years of neglect, two new drugs
(bedaquiline and delamanid) have been made available to manage difficult-to-treat MDR-/XDR-TB cases.
World Health Organization (WHO) guidelines published in March 2019 endorsed the possibility of
treating MDR-TB patients with a full oral regimen, following previous guidelines published in 2016 which
launched a shorter regimen lasting 9–10 months.
The objectives of this article are to review the main achievements in MDR-TB treatment through the
description of the existing WHO strategies, to discuss the main ongoing trials and to shed light on
potential future scenarios and revised definitions necessary to manage drug-resistant TB.
Introduction
Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-resistant (XDR)
tuberculosis (TB) has been challenging because of its prolonged duration (up to 20–24 months), toxicity,
costs and unsatisfactory outcomes [1, 2].
Until recently the recommended regimen for MDR-TB included, among other drugs, a fluoroquinolone (FLQ)
and a second-line injectable (amikacin, capreomycin or kanamycin) [3]. The importance of these two classes of
drugs in obtaining a successful outcome is reflected in the definition of a sub-category of MDR-TB, named
pre-XDR (extensively drug-resistant)-TB, i.e. MDR-TB strains also resistant to either any FLQ or any
second-line injectable [3]. In fact, this latter group, pre-XDR-TB patients, presented favourable outcomes at a
frequency intermediate between simple MDR (i.e. resistance to isoniazid and rifampicin only) and XDR-TB [4].
Methods
A non-systematic review of relevant scientific documents published in English (in Google Scholar and
other grey literature sources) was performed using the Google search engine without time limit. The
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following keywords were used: “tuberculosis”, “treatment regimens” and “World Health Organization
treatment guidelines”. All retrieved documents were evaluated by the authors and those considered
relevant for the purpose of the mini-review were included.
Results
In previous years, major efforts have been made towards establishing a standardised, scalable approach for
the treatment of MDR-/XDR-TB. The first effort began in the late 1990s when drug-resistant TB emerged
as a major problem threatening TB control (table 1) [5]. In response, in 1999, the World Health
Organization (WHO) and partners launched the programmatic approach named “DOTS-Plus” with the
first pilot projects beginning the following year [6]. DOTS-Plus was built upon the five elements of DOTS:
1) sustained political and financial commitment; 2) diagnosis of TB by quality ensured sputum smear
microscopy; 3) standardised short-course anti-TB treatment given under direct and supportive observation
(DOTS); 4) regular uninterrupted supply of high-quality anti-TB drugs; and 5) standardised recording and
reporting. DOTS-Plus introduced a rational use of second-line anti-TB drugs in resource-limited settings
with a high MDR-TB burden. In addition, the Green Light Committee facilitated access to second-line
drugs of proven quality and their proper use [7]. After collecting evidence of favourable results emerging
from Green Light Committee-approved field projects, the WHO issued the “Guidelines for the
programmatic management of drug-resistant tuberculosis” in 2006 [8]. One of the key recommendations
was that management of MDR-TB should be integrated into comprehensive national TB control plans as
suggested within the new Stop TB Strategy [9]. They also included the first “modern” categorisation of
TABLE 1 Historical list of recommended regimens for multidrug-resistant (MDR)/extensively drug-resistant (XDR) tuberculosis
(TB)
Name Year Main features/regimens Length of treatment [Ref.]
DOTS-PLUS 2000 Rational use of second-line drugs in resource-limited settings
GLC to facilitate access to proven quality second-line anti-TB drugs to
overcome difficulties in procurement and cost
[6, 7]
Guidelines for the
programmatic
management of
drug-resistant TB
2006 Management of MDR-TB to be integrated into comprehensive national
TB control plans
First “modern” categorisation of drugs used to treat MDR-TB into five
groups
Options for tailoring diagnosis and care to different epidemiological and
programmatic conditions worldwide
18 months after culture
conversion
[9]
Guidelines for the
programmatic
management of
drug-resistant TB:
emergency update
2008 Definition of XDR and acknowledgement of this threat
Recommendations on drug resistant management
Introduction of rapid DST
[10]
WHO guidelines for the
programmatic
management of
drug-resistant TB:
2011 update
2011 Importance of rapid DST stressed
Regimens including at least four, and ideally five, drugs likely to be effective
Drugs to be included are a FLQ, an injectable agent, ethionamide or
prothionamide, PZA and either cycloserine or para-amniosalicylic acid.
Other drugs such as EMB or group 5 drugs could be added, but they
should not be counted among the four effective drugs
20 months (with an
8-month intensive
phase)
[11]
WHO consolidated
guidelines on
drug-resistant TB
treatment
2019 Continued recommendation of using shorter regimen whenever possible
If using injectables use amikacin
Drugs reclassified into three groups (A, B and C) for the purpose of
composing the longer regimen:
Group A includes three drugs to be prioritised and used, if possible, in
all regimens: levofloxacin/moxifloxacin, BDQ and LZD
Group B includes two drugs to be possibly added to all regimens (CFZ
and cycloserine/terizidone)
Group C includes “other” agents (including injectables) to be used as a
substitute to complete a regimen of at least four drugs when agents from
groups A and B cannot be used
Longer regimen: may be
standardised or
individualised; duration
18–20 months, modified
depending upon patient
response
Shorter regimen:
9–12 months
[32]
WHO: World Health Organization; RR: rifampicin-resistant; GLC: Green Light Committee; DST: drug susceptibility testing; FLQ:
fluoroquinolone; PZA: pyrazinamide; EMB: ethambutol; CFZ: clofazimine; BDQ: bedaquiline; LZD: linezolid.
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drugs used to treat MDR-TB into five groups, recommending an 18 months of treatment after culture
conversion [8].
The 2008 “emergency update” of these guidelines introduced the new definition of XDR-TB, which had
meanwhile emerged in major outbreaks, and specific recommendations for its management, including the
use of rapid drug-susceptibility testing (DST), were included [10].
The following version of the WHO guidelines issued in 2011 stressed the importance of rapid DST and
updated the categories and types of drugs to be used [11]. Notwithstanding the low quantity and quality of
evidence, the recommended treatment of MDR-TB included at least four, and possibly five, drugs likely to
be effective for a recommended duration of 20 months (with an 8-month intensive phase) [11].
The first addition to these recommendations was based on new observational evidence of successful
outcomes obtained from a standardised 9–12-month regimen developed and tested by the International
Union AgainstTuberculosis and Lung Diseases, the so-called “Bangladesh regimen” [12]. This regimen
includes a 4–6 month intensive phase with a seven-drug regimen (kanamycin, moxifloxacin,
prothionamide, clofazimine, pyrazinamide, high-dose isoniazid and ethambutol) followed by a 5-month
course with moxifloxacin, clofazimine, pyrazinamide and ethambutol. The exclusion criteria are:
1) confirmed resistance or suspected ineffectiveness to a medicine in the shorter MDR-TB regimen (except
isoniazid resistance); 2) exposure to >1 second-line medicine in the shorter MDR-TB regimen for
>1 month; 3) intolerance to >1 medicine in the shorter MDR-TB regimen or risk of toxicity (e.g. drug–
drug interactions); 4) extrapulmonary disease; 5) pregnancy; and 6) at least one medicine in the shorter
MDR-TB regimen not available in the programme. This regimen, originally used in Bangladesh, was tested
in other countries with similar favourable outcomes [13–15]. This led the WHO to recommend its use by
national TB programmes under strict conditions in 2016 (if no listed exclusion criteria applicable to the
patient) [3]. In settings with high prevalence of “simple” MDR strains this regimen was expected to work
well. However, it seemed to have limitations in settings where a “mixture” of MDR strains was present, for
instance where there was additional resistance, especially to pyrazinamide, or where it is difficult to obtain
a complete resistance profile of isolated strains [16–19]. Pyrazinamide resistance, however, can often be
associated with rifampicin resistance [20].
In a recent study, SUN et al. [21] present interesting data from China in a prospective cohort of MDR-TB
cases where pyrazinamide resistance was or was not tested. The study results show that optimisation of
treatment regimens based on pyrazinamide DST significantly improves treatment outcomes [21].
The Bangladesh regimen was later tested in an international, randomised controlled trial (STREAM 1).
The final report has been published very recently, showing good results in the shorter regimen arm with
78.8% of patients achieving a favourable outcome [15]. Thus, this regimen constitutes a true innovation in
shortening MDR treatment proving that, under specific conditions, it is an alternative option to the longer
WHO regimen in simple MDR cases [14, 15]. Unfortunately, this regimen still includes an injectable agent
during the intensive phase thus exposing patients to the risk of ototoxicity and nephrotoxicity and the
unpleasant effects of its route of administration [13].
Over the past 2 years, a series of reports showed that treatment outcomes in patients with drug-resistant
TB could be improved using new combinations of drugs given for shorter periods of time, better selecting
the “old” drugs to include in the treatment regimen or introducing new drugs for prolonged periods of
time [15, 22–27].
A recent meta-analysis of individual patient data in MDR-TB treatment attempted to attribute a specific
weight to each drug that has been used in MDR-/XDR-TB treatment regimens [28]. The study compared
the association of each drug with failure or relapse versus treatment success. Treatment success was
positively associated with the use of linezolid, levofloxacin, carbapenems, moxifloxacin, bedaquiline and
clofazimine. Mortality was significantly reduced with the use of linezolid, levofloxacin, moxifloxacin or
bedaquiline. Surprisingly, compared with regimens without any injectable, amikacin provided only modest
benefits, while kanamycin and capreomycin were associated with worse outcomes. The negative effect of
the injectables on outcomes could be due to the decision by the treating clinicians to use them in the
worst clinical cases, based on the resistance profile or despite it. Another possible bias could be due to
changing drugs during the course of treatment or misclassification of treatment outcomes. Therefore,
rather than concluding that the injectables should be avoided, the study emphasised the relevance of the
use of later generation fluoroquinolones, bedaquiline, linezolid and clofazimine. What the study also
showed is that treatment outcomes can be improved when bedaquiline is used as a substitute for
second-line injectable agents [28].
As a result of all the information accumulated over the years, by 2017, at least 62 countries had introduced
shorter regimens for treatment of MDR-/rifampicin resistant-TB and 68 countries had started using
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bedaquiline [1]. In particular, bedaquiline has recently emerged as a key drug to be included in regimens
despite the fact that it received temporary approval after only a phase 2B clinical trial and without full
information on its efficacy and potential toxicity [1, 23]. Fortunately, despite initial concerns on possible
cardiac toxicity (QT interval prolongation on electrocardiogram), recent data show that such toxicity is
limited in severity and frequency, and is generally reversible [29, 30]. Nevertheless, particular attention in
monitoring QT is necessary when bedaquiline is given with other drugs with a potential to prolong the
QT interval, i.e. clofazimine, later-generation fluoroquinolones and delamanid [29].
Based on the evidence from the new studies and the meta-analysis cited above, in mid-2018 the WHO
issued a rapid communication and in March 2019 the updated consolidated guidelines, substantially
changing the approach to treatment of MDR-/XDR-TB [31, 32]. The updated guidelines address the role
of both the longer and shorter treatment regimens and reclassify the drugs used to compose the longer
(18–20 month) regimen into 3 groups (A, B and C) (table 1). Apart from the ranking by effectiveness or
toxicity, the choice of drugs in a regimen is also determined by factors such as: preference for oral over
injectable agents; results of DST; reliability of existing DST methods for second-line drugs; population
drug-resistance patterns and levels; history of previous use of the drugs; drug tolerability; and potential
drug–drug interactions. Finally, the WHO, while recommending the use of the shorter regimen whenever
possible, emphasised: 1) the need to exclude kanamycin and capreomycin from all regimens; and 2) to
replace them with amikacin if a second-line injectable is still necessary [32].
While this historical account summarises the past and present of MDR-/XDR-TB treatment, the question
that arises is, what does the future hold?
From what has been explained so far, the first logical conclusion is that there is a continuous need to study
new regimens, combining new and old drugs for different durations of time. There is also a need to revisit
drug resistance definitions based on the challenges to be faced by the introduction of new regimens [33].
The trials that have been planned or are ongoing are listed in table 2.
Recently the Global TB Alliance presented promising preliminary data from the Nix-TB trial conducted in
South Africa [34], the first clinical trial aiming to test a novel anti-TB regimen with the potential to be a
shorter, all oral and affordable treatment for XDR-TB and complex forms of MDR-TB. The Nix-TB
regimen consists of three drugs against which there is, currently, minimum potential resistance:
bedaquiline, pretomanid and linezolid. This regimen (BPaL) achieved a cure rate of 85–90% after a
6-month course of treatment. The final results for the full patient cohort will be available in 2019 and it is
expected that the new regimen could be approved for use by the second half of the year. For this regimen
to succeed on a wide scale, it will be imperative to safely use its three components and minimise the risk
of drug resistance to any of them. While minimum resistance to bedaquiline is expected for settings with
no exposure to this drug, in those countries that have already decided to use bedaquiline widely, the risk
of rapidly increasing resistance will need to be closely monitored to avoid treatment failures, deaths and
onset of future additional resistance [35]. Other challenges to the implementation of this regimen can
derive from linezolid toxicity and the occurrence of resistance to bedaquiline in those patients exposed to
clofazimine (due to the partial cross-resistance between the two drugs) [36].
A second regimen under testing by the Global Alliance in the trial SimpliciTB is the BPaMZ regimen
composed of bedaquiline, pretomanid, moxifloxacin and pyrazinamide. In the initial phase 2B trial, culture
negativity was obtained within 2 months of treatment, three times faster than among drug-susceptible TB
patients on the standard 6-month short-course regimen. The BPaMZ regimen is now being tested for all
types of TB as a potential shorter “universal regimen” and results are expected in 2021. The potential wide
use of the regimen will, as for BPaL, be conditional to minimisation of creation of resistance to its new
components. Concerningly, the presence of resistance to the fluoroquinolones and pyrazinamide
among rifampicin-resistant cases, although frequently low, is already well documented in certain settings
[20, 21, 37].
The studies listed in table 2 aim to provide a proof-of-concept that treatment of MDR-/XDR-TB can be
significantly shortened and fully oral through combinations of new and old anti-TB drugs. The likelihood
that from any of these studies a single regimen will emerge as the best and only one to be recommended
is, after all, low. Rather, one can expect that different options (in terms of type of drugs, dosages and
treatment duration) will be available in the future in the quest for more precision in treatment. For
instance, it is possible that more than one regimen will be adequate for simple MDR-TB while in the
presence of additional resistance patterns, single or combined (e.g. pyrazinamide, fluoroquinolones and
injectables), progressively fewer and fewer regimens will retain good performance and be recommended.
The final regimen will critically depend on a full and rapid understanding of the drug-resistance pattern
through the use of new technologies such as next-generation sequencing [38, 39].
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TABLE 2 Innovative ongoing trials for an “all-oral” treatment of multidrug-resistant (MDR)/extensively drug-resistant (XDR) tuberculosis (TB)
Trial number/
name
Type of TB
(MDR/XDR)
Study
phase
Regimens studied Promoter Duration
of new
regimen
Status Patients n
1 Nix# XDR 3 Pretomanid, bedaquiline and linezolid TB Alliance 6 months Ongoing >75¶
2 ZeNix XDR 3 Pretomanid, bedaquiline and linezolid (linezolid treatment dose
and duration are double-blinded)
TB Alliance 26 weeks Enrolling 180 (estimated)
3 STREAM MDR 3 A: local WHO standard
B: clofazimine, ethambutol, moxifloxacin and pyrazinamide
(40 weeks) + isoniazid, kanamycin and prothionamide (first
16 weeks)
C: bedaquiline, clofazimine, ethambutol, levofloxacin and
pyrazinamide (40 weeks) + isoniazid and prothionamide (first
16 weeks)
D: bedaquiline, clofazimine, levofloxacin and pyrazinamide
(28 weeks) + isoniazid and kanamycin (first 8 weeks)
IUATLD 36/56 weeks Enrolling Currently >300
4 NeXT MDR 3 Linezolid, bedaquiline, levofloxacin, pyrazinamide + ethionamide
or terizidone or high-dose INH
South African
investigators
6–9 months Not yet
recruiting
300 (estimated)
5 TB
PRACTECAL
MDR/XDR 2–3 A: local WHO standard
B: bedaquiline and pretomanid + linezolid, moxifloxacin
C: bedaquiline and pretomanid + linezolid, clofazimine
D: bedaquiline and pretomanid + linezolid
MSF 6 months Enrolling Currently >100
(630 estimated)
6 End TB MDR 3 A: bedaquiline, linezolid, moxifloxacin, pyrazinamide
B: bedaquiline, linezolid, clofazimine, levofloxacin, pyrazinamide
C: bedaquiline, delamanid, linezolid, levofloxacin, pyrazinamide
D: delamanid, clofazimine, levofloxacin, linezolid, pyrazinamide
E: delamanid, clofazimine, moxifloxacin, pyrazinamide
F: local WHO standard, including the possible use of
bedaquiline or delamanid
MSF and PIH 9 months Enrolling Currently >170
(750 estimated)
7 SimpliciTB MDR (or single
resistance to
isoniazid or
rifampicin)
2 Bedaquiline, pretomanid, moxifloxacin, pyrazinamide TB Alliance 6 months Enrolling Currently >10 (150
estimated)
8 MDR-END MDR 2 Delamanid, linezolid, levofloxacin and pyrazinamide versus local
WHO standard
Seoul National
University Hospital
9–12 months Enrolling (238 estimated)
IUATLD: International Union Against Tuberculosis and Lung Diseases; MSF: Médecins Sans Frontières; PIH: Partners In Health; WHO: World Health Organization; INH: isoniazid:
#: definitive results pending; ¶: information reported only for this number of patients.
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Discussion
Therefore, the scale-up of regimens may also require new definitions of drug resistance that encompass all
new and old drugs recommended as component of regimens [33] and are useful not only for surveillance
purposes but also to inform treatment choices. In this scenario, specific resistance profiles (e.g. MDR,
MDR + pyrazinamide, MDR + fluoroquinolone(s), XDR, XDR + bedaquiline and MDR + bedaquiline)
will match appropriate regimens. At the same time, through the use of modern technology including
sequencing, therapeutic drug monitoring, clinical decision support systems and digital solutions, even
patients experiencing multiple failures and/or toxicities with unusual and/or more complex resistance
profiles could be cured. In this regard, national and international bodies of experts (TB consilia) may be
important in supporting personalised design of regimens for challenging resistance patterns [40].
After years of uncertainty in the search for optimal treatments for MDR-/XDR-TB, some of the
mentioned recent breakthroughs are fostering progress. The ongoing and planned clinical trials will help
care providers and national programmes to offer better, shorter, more effective and safer regimens to treat
people affected by MDR-/XDR-TB while contributing to elimination of this disease.
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